Markets:

Overview

News

Currencies

International

Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗

November 13, 2021

Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.

Via Talk Markets

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates ↗

November 09, 2021

Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...

Via Benzinga

Blueprint Medicines Corp (BPMC) Q3 2021 Earnings Call Transcript ↗

October 28, 2021

BPMC earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

June 17, 2021

Blueprint Medicines (NASDAQ:BPMC) has observed the followi...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar ↗

August 05, 2021

Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Blueprint Medicines: Q2 Earnings Insights ↗

July 29, 2021

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗

June 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...

Via Benzinga

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs ↗

June 13, 2021

Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗

June 01, 2021

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...

Via Benzinga

Recap: Blueprint Medicines Q1 Earnings ↗

April 29, 2021

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past...

Via Benzinga

1 Cancer Stock to Buy and Hold for the Next Decade ↗

April 17, 2021

Blueprint Medicines is setting itself up to become the leader in precision oncology.

Via The Motley Fool

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight ↗

April 10, 2021

Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...

Via Benzinga

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

Headline News about Blueprint Medicines Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today